Trial Profile
Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active RA. A Multicenter Post-Marketing Observational Study in Routine Clinical Use.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2012
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms FALLA
- Sponsors Abbott Laboratories
- 30 Dec 2011 Actual patient number changed from 84 to 82 as reported by ClinicalTrials.gov.
- 21 Mar 2011 Actual initiation date changed from Mar 2008 to Apr 2008 as reported by ClinicalTrials.gov.
- 21 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.